Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.74 |
| ▸ | MAX | P61244 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.65 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.61 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.51 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1124983 | 1.00 | MYC (0.74) | MYCMAXALDH1A1SMN1; SMN2HSD17B3 | |
| SCHEMBL20816067 | 0.85 | MYC (1.00) | MYCMAXALDH1A1SMN1; SMN2HSD17B3 | |
| SCHEMBL20816065 | 0.85 | MYC (1.00) | MYCMAXALDH1A1SMN1; SMN2HSD17B3 | |
| SCHEMBL15330387 | 0.80 | PTPN12 (0.79) | MEN1KMT2APTPN12PTPN22 | |
| SCHEMBL15330386 | 0.80 | PTPN12 (0.79) | MEN1KMT2APTPN12PTPN22 | |
| SCHEMBL8205852 | 0.79 | HSD17B3 (0.62) | MYCMAXALDH1A1SMN1; SMN2HSD17B3 | |
| SCHEMBL8205853 | 0.79 | HSD17B3 (0.62) | MYCMAXALDH1A1SMN1; SMN2HSD17B3 | |
| SCHEMBL20005672 | 0.78 | MAPK1 (0.72) | MYCMAXALDH1A1SMN1; SMN2HSD17B3 | |
| SCHEMBL18103053 | 0.78 | MAPK1 (0.72) | MYCMAXALDH1A1SMN1; SMN2HSD17B3 | |
| SCHEMBL18545476 | 0.77 | CISD1 (0.55) | MYCMAXALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | MYC 3980/4885MAX 4518/4885ALDH1A1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.